Week 35 complete: Cancer levels mostly stable

Week 35 chemo complete: cancer levels mostly stable

Almost 2 weeks ago, treat I went in for my monthly big blood test to determine what my Hematology profile is (how my body responds overall to my chemo treatment) and learn what my Serum Proteins (Electrophoresis & Immunoglobulins) are, which are my cancer levels. The process was a bit longer than I would have liked. As can happen, my left arm was tapped out, so two attempts were unsuccessful. My right arm is my backup, so I was relieved that the lab technician could successfully draw blood after one try. As I’ve stated before, here in BC I use an online service called myehealth, to get free access to my lab results as soon as available (24 – 30 hours for big test, same day for small test). I’m happy my results are mostly stable.

The igG is the general cancer marker used by Hematologists to measure progress in a patient’s cancer level, however each patient can be unique. My particular multiple myeloma resides in the Beta-2 microglobulin region, that is the specific protein marker that we (my Hematologist and I) watch to determine the progress of the chemo treatment on my myeloma each month. It is the best indicator of how effective my Pomalyst chemo is.

Serum Proteins (Electrophoresis & Immunoglobulins) (g/L)
Date Albumin Beta Globulin 2 Gamma Globulin igG igA igM
Reference Range 34.0-53.0 1.8 – 4.8 5.1 – 15.0 6.7 – 15.2 .70 – 4.00 .40 – 2.30
Oct 48.5 9.0 4.0 13.3 .82 .43
Sept 44.1 9.2 3.2 12.9 .66 .31
Aug 47.7 10.7 3.0 14.8 .62 .32
July 45.8 11.4 3.6 15.7 .56 .37
June 41.2 15.2 3.9 16.5 .49 .40
May 42 17.2 2.5 18.7 .28 .33
Apr 44.4 19.2 1.5 21.4 .29 .41
Mar 39.1 27.1 2.6 27.5 .26 .50
Feb 38.9 33.9 3.0 36.1 .33 .53
Jan 39.3 30.6 3.7 33.4 .29 .22

My Hematology Profile is the Complete Blood Count test I have every 2 weeks that measures my overall health.

Hematology Profile
Date WBC Hemoglobin Platelet Count Neutrophils
Reference Range 4.0 – 11.0 135 – 170 150 – 400 2.0 – 8.0
Oct 10.5 139 329 8.8
Sept 5.3 130 363 4.4
Sept 13.7 122 304 5.2
Aug 6.1 130 378 4.9
Aug 12.0 133 329 8.3
July 12.8 131 302 9.47
July 4.8 123 386 3.8
June 10.6 124 281 8.0
June 6.5 122 439 4.7
May 12.4 118 271 8.9
May 10.0 118 320 5.2
Apr 12.5 123 297 9.8
Apr 7.6 113 357 3.9
Mar 7.0 133 247 5.6
Mar 6.8 127 467 5.2
Feb 5.5 133 191 4.6
Jan 4.4 129 206 2.3

To recap: On Sunday, October 11th, I completed Cycle 9 Week 3. I have Multiple Myeloma and anemia, a rare blood cancer. It is incurable, but treatable. From February to November 2013, I received Velcade chemo through weekly in-hospital injections as an outpatient. Since February 9th 2015, I have been on Pomalyst and dexamethasone chemo treatment (Pom/dex). I started Cycle 10 on October 19th.

Weekly chemo-inspired self-portraits can be viewed in my flickr album.

UBC Wreck BeachApril 2014: UBC Wreck Beach

About tyfn

From December 2019 I've been on Darzalex (daratumumab) IV chemo with Velcade (Bortezomib) injection chemo + dexamethasone. Have Multiple Myeloma + anemia, a rare incurable cancer of the immune system. Life goal: To spread awareness about Multiple Myeloma through my self-portraits. UBC MSc Grad.
This entry was posted in Cancer and tagged , , , , , , , , , . Bookmark the permalink.

2 Responses to Week 35 complete: Cancer levels mostly stable

  1. Christopher says:

    Hi there,
    am just listening to superbetter and stumbled on your work. You are a true inspiration and artist! Thank you for putting yourself and your work out there! Stay strong!
    All the very best wishes from germany,
    Chris

    • tyfn says:

      Thanks Chris. That was during a previous chemo in 2013. Doing SuperBetter really helped me get back into doing self-portraits at that time. I’m now on another chemo and staying positive each day. For this chemo, I’m taking weekly photos that help provide an awareness about multiple myeloma. I have the SuperBetter book that Jane sent me and I’ve begun to read it. I hope you have an amazing weekend! Thanks for reaching out.

Leave a Reply

Your email address will not be published. Required fields are marked *